Skip to main content
Premium Trial:

Request an Annual Quote

Early Exposure

Jodie Spitze at Xconomy says that "bioinformatics education should start in high school." Spitze, a high school science teacher, notes that most of her students who excel in science and math are interested in pursuing careers in human and veterinary medicine. In an effort to get students interested in basic discovery research, Spitze emphasizes that one of the most exciting advances in science is the merger of biology and technology. "What is especially exciting is that this technology is available to all, including high school students," she writes. As a teacher, Spitze says she worries whether she's "doing enough to prepare my students for the careers that await them." But programs such as the National Science Foundation's Innovative Technology Experiences for Students and Teachers are a big help. "Just seeing a scientist that looks like them can be enough to allow some students to envision themselves in similar careers," she says of the effectiveness of programs like the Bio-ITEST Bioinformatics Workshop.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.